A 2 year old boy presents with abnormal pigmentation around eyes with abnormal eye movements. It is noted that child has spontaneous bursts of non rhythmic conjugate eye movements in various directions. He also suffers from hypotonia and myoclonus. Fuher physical examination reveals an abdominal mass. CT scan is done with the following findings: Which of the following drug is approved for the above clinical scenario?

**Core Concept**
The clinical presentation suggests a diagnosis of **neuroblastoma**, a common extracranial solid tumor in children, often presenting with abdominal masses and paraneoplastic syndromes such as **opsoclonus-myoclonus syndrome**. This syndrome is characterized by **opsoclonus** (irregular, rapid eye movements), **myoclonus** (sudden muscle jerks), and **ataxia**.

**Why the Correct Answer is Right**
Since the question is incomplete and doesn't specify the correct answer or the options provided, a general approach to treating neuroblastoma, especially in the context of opsoclonus-myoclonus syndrome, involves **immunomodulatory therapy** and **chemotherapy**. However, without specific details on the options, it's challenging to pinpoint the exact drug approved for this scenario.

**Why Each Wrong Option is Incorrect**
**Option A:** Without knowing the specific drug, it's impossible to assess its correctness.
**Option B:** Similarly, without details, the appropriateness of this option cannot be determined.
**Option C:** This option's validity is also unknown due to lack of information.
**Option D:** The correctness of this choice remains unspecified.

**Clinical Pearl / High-Yield Fact**
In patients with neuroblastoma presenting with opsoclonus-myoclonus syndrome, **early recognition and treatment** are crucial for improving neurological outcomes. **ACTH** (adrenocorticotropic hormone) and **corticosteroids** may be used to manage symptoms of the syndrome.

**Correct Answer:** Correct Answer: D. Dinutuximab.

✓ Correct Answer: C. Dinutuximab